Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Autoimmunity Highlights
Published in: Autoimmunity Highlights 1/2016

Open Access 01-12-2016 | Review Article

Behçet’s disease physiopathology: a contemporary review

Authors: Mohamad J. Zeidan, David Saadoun, Marlene Garrido, David Klatzmann, Adrien Six, Patrice Cacoub

Published in: Autoimmunity Highlights | Issue 1/2016

Login to get access

Abstract

Behçet’s disease, also known as the Silk Road Disease, is a rare systemic vasculitis disorder of unknown etiology. Recurrent attacks of acute inflammation characterize Behçet’s disease. Frequent oral aphthous ulcers, genital ulcers, skin lesions and ocular lesions are the most common manifestations. Inflammation is typically self-limiting in time and relapsing episodes of clinical manifestations represent a hallmark of Behçet’s disease. Other less frequent yet severe manifestations that have a major prognostic impact involve the eyes, the central nervous system, the main large vessels and the gastrointestinal tract. Behçet’s disease has a heterogeneous onset and is associated with significant morbidity and premature mortality. This study presents a current immunological review of the disease and provides a synopsis of clinical aspects and treatment options.
Appendix
Available only for authorised users
Literature
1.
Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gonçalves O, Valente J (2009) Behçet’s disease—a contemporary review. J Autoimmun 32(3–4):178–188CrossRefPubMed
2.
Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR (1999) Behçet’s disease, the silk road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54(3):213–220CrossRefPubMed
3.
Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A et al (2007) Anti-TNF therapy in the management of behçet’s disease-review and basis for recommendations. Rheumatology (Oxford) 46(5):736–741CrossRef
4.
Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, Cacoub P (2010) Mortality in Behçet’s disease. Arthritis Rheum 62(9):2806–2812CrossRefPubMed
5.
6.
Sfikakis PP (2002) Behçet’s disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis 61(Suppl 2):51–53CrossRef
7.
Yazici H, Akokan G, Yalçin B, Müftüoğlu A (1977) The high prevalence of HLA-B5 in Behçet’s disease. Clin Exp Immunol 30(2):259–261PubMedPubMedCentral
8.
Lawton G, Bhakta BB, Chamberlain MA, Tennant A (2004) The Behçet’s disease activity index. Rheumatology (Oxford) 43(1):73–78CrossRef
9.
Savey L, Resche-Rigon M, Wechsler B, Comarmond C, Piette JC, Cacoub P, Saadoun D (2014) Ethnicity and association with disease manifestations and mortality in Behçet’s disease. Orphanet J Rare Dis 27(9):42CrossRef
10.
11.
Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C et al (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet 42(8):698–702CrossRefPubMedPubMedCentral
12.
Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi Huong D, Resche-Rigon M et al (2010) Azathioprine in severe uveitis of Behçet’s disease. Arthritis Care Res (Hoboken). 62(12):1733–1738CrossRefPubMed
13.
Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong D Le T, Amoura Z et al (2012) Immunosuppressants reduce venous thrombosis relapse in Behçet’s disease. Arthritis Rheum 64(8):2753–2760CrossRefPubMed
14.
Kump LI, Moeller KL, Reed GF, Kurup SK, Nussenblatt RB, Levy-Clarke GA (2008) Behçet’s disease: comparing 3 decades of treatment response at the national eye institute. Can J Ophthalmol 43(4):468–472CrossRefPubMedPubMedCentral
15.
16.
Alpsoy E, Donmez L, Bacanli A, Apaydin C, Butun B (2003) Review of the chronology of clinical manifestations in 60 patients with Behçet’s disease. Dermatology 207(4):354–356CrossRefPubMed
17.
Al-Araji A (2009) Neuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol 8(2):192CrossRefPubMed
18.
Arai Y, Kohno S, Takahashi Y, Miyajima Y, Tsutusi Y (2006) Autopsy case of neuro-Behçet’s disease with multifocal neutrophilic perivascular inflammation. Neuropathology 26(6):579–585CrossRefPubMed
19.
Hadfield MG, Aydin A, Lippman HR, Sanders KM (1997) Neuro-Behçet’s disease. Clin Neuropathol 16(2):55–60PubMed
20.
Noel N, Bernard R, Wechsler B, Resche-Rigon M, Depaz R, Le Thi Huong Boutin D et al (2014) Long-term outcome of neuro-Behçet’s disease. Arthritis Rheum 66(5):1306–1314CrossRef
21.
Kidd D (2012) Neurological complications of Behçet’s syndrome. Curr Neurol Neurosc Rep 12(6):675–679CrossRef
22.
Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C et al (2001) Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 248(2):95–103CrossRefPubMed
23.
Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive neuro-Behçet’s syndrome. J Neurol Sci 272(1):99–105CrossRefPubMed
24.
Saadoun D, Wechsler B, Resche-Rigon M, Trad S, Le Thi Huong D, Sbai A et al (2009) Cerebral venous thrombosis in Behçet’s disease. Arthritis Rheum 61(4):518–526CrossRefPubMed
25.
Akman-Demir G (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. Brain 122(11):2171–2182CrossRefPubMed
26.
Kizilkilic O, Albayram S, Adaletli I, Ak H, Islak C, Kocer N (2003) Endovascular treatment of Behçet’s disease-associated intracranial aneurysms: report of two cases and review of the literature. Neuroradiology 45(5):328–334CrossRefPubMed
27.
Öktem-Tanör Ö, Baykan-Kurt B, Gürvit IH, Akman-Demir G, Serdaroğlu P (1999) Neuropsychological follow-up of 12 patients with neuro-Behçet’s disease. J Neurol 246(2):113–119CrossRefPubMed
28.
Saadoun D, Asli B, Wechsler B, Houman H, Geri G, Desseaux K et al (2012) Long-term outcome of arterial lesions in Behçet’s disease: a series of 101 patients. Medicine (Baltimore) 91(1):18–24CrossRef
29.
Desbois A, Wechsler B, Cluzel P, Helft G, Boutin D, Piette JC et al (2014) Cardiovascular involvement in Behçet’s disease. Rev Med Int 35(2):103–111CrossRef
30.
Tursen U, Gurler A, Boyvat A (2003) Evaluation of clinical findings according to sex in 2313 turkish patients with Behçet’s disease. Int J Dermatol 42(5):346–351CrossRefPubMed
31.
Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V et al (2003) The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82(1):60–76CrossRefPubMed
32.
Desbois A, Rautou P, Biard L, Belmatoug N, Wechsler B, Resche-Rigon M et al (2014) Behçet’s disease in Budd-Chiari syndrome. Orphanet J Rare Dis 9(1):104CrossRefPubMedPubMedCentral
33.
Hamuryudan V, Yurdakul S, Moral F et al (1994) Pulmonary arterial aneurysms in behçet’s syndrome: a report of 24 cases. Br J Rheumatol 33(1):48–51CrossRefPubMed
34.
Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D et al (2011) Critical role of IL-21 in modulating Th17 and regulatory T cells in Behçet’s disease. J Allergy Clin Immunol 128(3):655CrossRefPubMed
35.
Atzeni F, Sarzi-Puttini P, Doria A, Boiardi L, Pipitone N, Salvarani C (2005) Behçet’s disease and cardiovascular involvement. Lupus 14(9):723–726CrossRefPubMed
36.
Ait Badi MA, Zyani M, Kaddouri S, Niamane R, Hda A, Algayres J (2008) Les manifestations articulaires de la maladie de Behçet. À propos de 79 cas. Rev Med Int 29(4):277–282CrossRef
37.
Kaklamani VG, Vaiopoulos G, Kaklamanis PG (1998) Behçet’s disease. Sem Arthritis Rheum 27(4):197–217CrossRef
38.
Kastner DL. Intermittent and periodic arthritic syndromes. In: Koopman WJ (ed.) Arthritis and allied conditions: a textbook of rheumatology. Vol. 1. 13th ed. Baltimore: Williams and Wilkins; 1997:1279–1306
39.
Beales IL (1998) Gastrointestinal involvement in Behçet’s syndrome. Am J Gastroenterol 93(12):2633CrossRefPubMed
40.
41.
Lee KS, Kim SJ, Lee BC, Yoon DS, Lee WJ, Chi HS (1997) Surgical treatment of intestinal Behçet’s disease. Yonsei Med J 38(6):455–460CrossRefPubMed
42.
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11CrossRefPubMed
43.
Link J, Söderström M, Olsson T, Höjeberg B, Ljungdahl A, Link H (1994) Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann Neurology 36(3):379–386CrossRef
44.
Cho SB, Cho S, Bang D (2012) New insights in the clinical understanding of Behçet’s disease. Yonsei Med J 53(1):35–42CrossRefPubMed
45.
International study group for Behçet’s disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335(8697):1078–1080
46.
Türsen Ü (2009) Activation markers in Behçet disease. Turkderm 43:74–86
47.
Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373–384CrossRefPubMed
48.
de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A (2009) HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 61(10):1287–1296CrossRefPubMed
49.
Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M (1982) Close association of HLA-Bw51 with Behçet’s disease. Arch Ophthalmol 100(9):1455–1458CrossRefPubMed
50.
Shahneh FZ, Hamzavi F, Bayazi B, Bandehagh A, Baradaran B (2013) New insights into HLA class I association to Behçet’s syndrome in Iranian Azari patients. Auto Immun Highlights 4(3):101–102CrossRefPubMedPubMedCentral
51.
Gül A (2014) Genetics of Behçetʼs disease: lessons learned from genomewide association studies. Curr Opin Rheumatol 26:56–63CrossRefPubMed
52.
53.
Ombrello MJ, Kirino Y, de Paul Bakker IW, Gül A, Kastner DL, Remmers EF (2014) Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci USA 111:8867–8872CrossRefPubMedPubMedCentral
54.
Kobayashi M, Ito M, Nakagawa A, Matsushita M, Nishikimi N, Sakurai T, Nimura Y (2000) Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease. Histopathology 36(4):362–371CrossRefPubMed
55.
Lehner T (1997) The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet’s disease. Int Rev Immunol 14(1):21–32CrossRefPubMed
56.
Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C et al (2015) Behçet’s syndrome patients exhibit specific microbiome signature. Autoimmun Rev 14(4):269–276CrossRefPubMed
57.
Hirohata S, Oka H, Mizushima Y (1992) Streptococcal-related antigens stimulate production of IL6 and interferon-γ by T cells from patients with Behçet’s disease. Cell Immunol 140(2):410–419CrossRefPubMed
58.
The Matzinger P, Model Danger (2002) A Renewed Sense of Self. Science. 296:301–305
59.
Medzhitov R, Janeway CA (2002) Decoding the patterns of self and non self by the innate immune system. Science 296:298–300CrossRefPubMed
60.
Direskeneli H (2006) Autoimmunity vs autoinflammation in Behcet’s disease: do we oversimplify a complex disorder? Rheumatology (Oxford) 45:1461–1465CrossRef
61.
62.
Hirohata S (2008) Histopathology of central nervous system lesions in Behçet’s disease. J Neurol Sci 267(1):41–47CrossRefPubMed
63.
Kidd G, Kivisäkk P, Ransohoff RM (2003) Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 3(7):569–581CrossRefPubMed
64.
Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF et al (2004) Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of blimp-1 and bcl-6. J Immunol 173(9):5361CrossRefPubMed
65.
Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L (2008) Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172(1):146–155CrossRefPubMedPubMedCentral
66.
Anderson MS, Bluestone JA (2005) The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23(1):447–485CrossRefPubMed
67.
Bucher C, Koch L, Vogtenhuber C, Goren E, Munger M, Panoskaltsis-Mortari A et al (2009) IL-21 blockade reduces graft-versus-host-disease mortality by supporting inducible T regulatory cell generation. Blood 114(26):5375–5384CrossRefPubMedPubMedCentral
68.
O’Garra A, Rouleau M, Antonenko S, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389(6652):737–742CrossRefPubMed
69.
Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB et al (2007) Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26(3):371–381CrossRefPubMed
70.
Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25(1):821–852CrossRefPubMed
71.
Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C (2007) STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 282(13):9358–9363CrossRefPubMed
72.
Lee JW, Wang P, Kattah MG, Youssef S, Steinman L, DeFea K, Straus DS (2008) Differential regulation of chemokines by IL-17 in colonic epithelial cells. J Immunol 181(9):6536CrossRefPubMed
73.
Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol. 2010; 2009;30(1):80–9
74.
de Pineton Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 11(10):687–698CrossRef
75.
76.
77.
Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M et al (2007) Human Th17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13(10):1173–1175CrossRefPubMedPubMedCentral
78.
Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V et al (2011) Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365:2067–2077CrossRefPubMed
79.
Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K et al (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448(7152):480–483CrossRefPubMed
80.
Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi F (2005) Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 174(5):2696–2701CrossRefPubMed
81.
Brustle A, Heink S, Huber M, Rosenplänter C, Stadelmann C, Yu P et al (2007) The development of inflammatory Th-17 cells requires interferon-regulatory factor 4. Nat Immunol 8(9):958–966CrossRefPubMed
82.
Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A et al (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30(6):899–911CrossRefPubMed
83.
Bottinelli D, Uccelli A, Engelhardt B, Benvenuto F, Bottinelli D, Lira S et al (2009) C-C chemokine receptor 6-regulated entry of T H-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 10(5):514–523CrossRefPubMed
84.
Engelhardt B, Wolburg-Buchholz K, Wolburg H (2001) Involvement of the choroid plexus in central nervous system inflammation. Micros Res Tech 52(1):112–129CrossRef
85.
Chen Q, Yang W, Gupta S, Biswas P, Smith P, Bhagat G, Pernis AB (2008) IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity 29(6):899–911CrossRefPubMedPubMedCentral
86.
Fantini MC, Rizzo A, Fina D, Caruso R, Becker C, Neurath MF et al (2007) IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 37(11):3155–3163CrossRefPubMed
87.
Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H (1999) Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5(2):101–104CrossRefPubMed
88.
Dagur PK, Biancotto A, Stansky E, Sen HN, Nussenblatt RB, McCoy JP (2014) Secretion of interleukin-17 by CD8+ T cells expressing CD146 (MCAM). Clin Immunol 152:36–47CrossRefPubMedPubMedCentral
89.
Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ et al (2006) The orphan nuclear receptor RORgammat directs the differentiation program of pro-inflammatory IL-17+ T helper cells. Cell 126(6):1121CrossRefPubMed
90.
Seder RA, Paul WE, Davis MM, de Fazekas St Groth B (1992) The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 176(4):1091–1098CrossRefPubMed
91.
Wu X, Tan Y, Xing Q, Wang S (2013) IL-21 accelerates xenogeneic graft-versus-host disease correlated with increased B-cell proliferation. Protein Cell 4(11):863–871CrossRefPubMedPubMedCentral
92.
Habib T, Senadheera S, Weinberg K, Kaushansky K (2002) The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 41(27):8725CrossRefPubMed
93.
Touzot M, Cacoub P, Bodaghi B, Soumelis V, Saadoun D (2015) IFN-α induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease. Autoimmun Rev 14(5):370–375CrossRefPubMed
94.
Comarmond C, Wechsler B, Bodaghi B, Cacoub P, Saadoun D (2014) Biotherapies in Behçet’s disease. Autoimmun Rev 13(7):762–769CrossRefPubMed
95.
Takamoto M, Kaburaki T, Numaga J, Fujino Y, Kawashima H (2007) Long-term infliximab treatment for behçet’s disease. Jpn J Ophthalmol 51(3):239–240CrossRefPubMed
96.
Sbaï A, Wechsler B, Duhaut P, Du-Boutin LT, Amoura Z, Cacoub P et al (2003) Neuro-Behçet’s disease (isolated cerebral thrombophlebitis excluded). Clinical pattern, prognostic factors, treatment and long term follow-up. Adv Exp Med Biol 528:371–376CrossRefPubMed
97.
Wechsler B, Lê Thi Huong DB, Saadoun D (2009) EULAR recommendations for the management of Behçet’s disease: evidence-based or experience-based medicine. Rev Med Interne 30(11):939–941CrossRefPubMed
98.
Hatemi G, Melikoglu M, Tunc R et al (2015) Apremilast for Behçet’s syndrome–a phase 2, placebo-controlled study. N Engl J Med 372:1510CrossRefPubMed
Metadata
Title
Behçet’s disease physiopathology: a contemporary review
Authors
Mohamad J. Zeidan
David Saadoun
Marlene Garrido
David Klatzmann
Adrien Six
Patrice Cacoub
Publication date
01-12-2016
Publisher
Springer International Publishing
Published in
Autoimmunity Highlights / Issue 1/2016
Print ISSN: 2038-0305
Electronic ISSN: 2038-3274
DOI
https://doi.org/10.1007/s13317-016-0074-1

Other articles of this Issue 1/2016

Autoimmunity Highlights 1/2016 Go to the issue

Short Communication

Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection

Case Report

An unusual association of three autoimmune disorders: celiac disease, systemic lupus erythematosus and Hashimoto’s thyroiditis

Original Article

International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results

Review Article

The relative merits of therapies being developed to tackle inappropriate (‘self’-directed) complement activation

Original Article

The ANA-reflex test as a model for improving clinical appropriateness in autoimmune diagnostics

Original Article

Intraepithelial lymphocytes subsets in different forms of celiac disease

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits